Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 345 participants.
Also called NCT04765657
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 345 participants
- Sponsor
- Registry
-
NCT04765657
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China, Singapore, South Korea, Taiwan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04765657. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (actual); primary completion 2022-06-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- inclisiran sodium
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct04765657- Content hash
cc522d91050e13ed4ecf8bd3976a4b05859b2ce2797e47bfb53d329295b4c217